1
Multiple studies have confirmed the contribution of rare de novo copy number variations to the risk for autism spectrum disorders [1] [2] [3] . But whereas de novo single nucleotide variants have been identified in affected individuals 4 , their contribution to risk has yet to be clarified. Specifically, the frequency and distribution of these mutations have not been well characterized in matched unaffected controls, and such data are vital to the interpretation of de novo coding mutations observed in probands. Here we show, using whole-exome sequencing of 928 individuals, including 200 phenotypically discordant sibling pairs, that highly disruptive (nonsense and splice-site) de novo mutations in brain-expressed genes are associated with autism spectrum disorders and carry large effects. On the basis of mutation rates in unaffected individuals, we demonstrate that multiple independent de novo single nucleotide variants in the same gene among unrelated probands reliably identifies risk alleles, providing a clear path forward for gene discovery. Among a total of 279 identified de novo coding mutations, there is a single instance in probands, and none in siblings, in which two independent nonsense variants disrupt the same gene, SCN2A (sodium channel, voltage-gated, type II, a subunit), a result that is highly unlikely by chance.
We completed whole-exome sequencing in 238 families from the Simons Simplex Collection (SSC), a comprehensively phenotyped autism spectrum disorders (ASD) cohort consisting of pedigrees with two unaffected parents, an affected proband, and, in 200 families, an unaffected sibling 5 . Exome sequences were captured with NimbleGen oligonucleotide libraries, subjected to DNA sequencing on the Illumina platform, and genotype calls were made at targeted bases (Supplementary Information) 6, 7 . On average, 95% of the targeted bases in each individual were assessed by $8 independent sequence reads; only those bases showing $20 independent reads in all family members were considered for de novo mutation detection. This allowed for analysis of de novo events in 83% of all targeted bases and 73% of all exons and splice sites in the RefSeq hg18 database (http://www.ncbi.nlm.nih.gov/RefSeq/; Supplementary Table 1; Supplementary Data 1). Given uncertainties regarding the sensitivity of detection of insertion-deletions, case-control comparisons reported here consider only single base substitutions (Supplementary Information). Validation was attempted for all predicted de novo single nucleotide variants (SNVs) via Sanger sequencing of all family members, with sequence readers blinded to affected status; 96% were successfully validated. We determined there was no evidence of systematic bias in variant detection between affected and unaffected siblings through comparisons of silent de novo, non-coding de novo, and novel transmitted variants ( Fig. 1a ; Supplementary Figs 1-5 ; Supplementary Information).
Among 200 quartets (Table 1) , 125 non-synonymous de novo SNVs were present in probands and 87 in siblings: 15 of these were nonsense (10 in probands; 5 in siblings) and 5 altered a canonical splice site (5 in probands; 0 in siblings). There were 2 instances in which de novo SNVs were present in the same gene in two unrelated probands; one of these involved two independent nonsense variants ( Table 2) . Overall, the total number of non-synonymous de novo SNVs was significantly greater in probands compared to their unaffected siblings (P 5 0.01, two-tailed binomial exact test; Fig. 1a ; Table 1 ) as was the odds ratio (OR) of non-synonymous to silent mutations in probands versus siblings (OR 5 1.93; 95% confidence interval (CI), 1.11-3.36; P 5 0.02, asymptotic test; Table 1 ). Restricting the analysis to nonsense and splice site mutations in brain-expressed genes resulted in substantially increased estimates of effect size and demonstrated a significant difference in cases versus controls based either on an analysis of mutation burden (N 5 13 versus 3; P 5 0.02, two-tailed binomial exact test; Fig. 1a To determine whether factors other than diagnosis of ASD could explain our findings, we examined a variety of potential covariates, including parental age, IQ and sex. We found that the rate of de novo SNVs indeed increases with paternal age (P 5 0.008, two-tailed Poisson regression) and that paternal and maternal ages are highly correlated (P , 0.0001, two-tailed linear regression). However, although the mean paternal age of probands in our sample was 1.1 years higher than their unaffected siblings, re-analysis accounting for age did not substantively alter any of the significant results reported here (Supplementary Information). Similarly, no significant relationship was observed between the rate of de novo SNVs and proband IQ (P $ 0.19, two-tailed linear regression, Supplementary Information) or proband sex (P $ 0.12, two-tailed Poisson regression; Supplementary Fig. 6 ; Supplementary Information).
Overall, these data demonstrate that non-synonymous de novo SNVs, and particularly highly disruptive nonsense and splice-site de novo mutations, are associated with ASD. On the basis of the conservative assumption that de novo single-base coding mutations observed in siblings confer no autism liability, we estimate that at least 14% of affected individuals in the SSC carry de novo SNV risk events (Supplementary Information). Moreover, among probands and considering brain-expressed genes, an estimated 41% of non-synonymous de novo SNVs (95% CI, 21-58%) and 77% of nonsense and splice site de novo SNVs (95% CI, 33-100%) point to bona fide ASD-risk loci (Supplementary Information).
We next set out to evaluate which of the particular de novo SNVs identified in our study confer this risk. On the basis of our prior work . 'All' refers to all RefSeq genes in hg18, 'Brain' refers to the subset of genes that are brain-expressed 24 and 'Non-syn' to non-synonymous SNVs (including missense, nonsense and splice site SNVs). Error bars represent the 95% confidence intervals and P values are calculated with a two-tailed binomial exact test. b, The proportion of transmitted variants in brain-expressed genes is equal between 200 probands (red) and matched unaffected siblings (blue) for all mutation types and allele frequencies, including common ($1%), rare (,1%) and novel (single allele in one of the 400 parents); in contrast, both non-synonymous and nonsense de novo variants show significant enrichment in probands compared to unaffected siblings (73.7% versus 66.7%, P 5 0.01, asymptotic test and 9.5% versus 3.1%, P 5 0.01 respectively). c, The frequency distribution of brain-expressed nonsynonymous de novo SNVs is shown per sample for probands (red) and siblings (blue). Neither distribution differs from the Poisson distribution (black line), suggesting that multiple de novo SNVs within a single individual do not confirm ASD risk. Nonsense { represents the combination of nonsense and splice site SNVs. 
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we hypothesized that estimating the probability of observing multiple independent de novo SNVs in the same gene in unrelated individuals would provide a more powerful statistical approach to identifying ASD-risk genes than the alternative of comparing mutation counts in affected versus unaffected individuals. Consequently, we conducted simulation experiments focusing on de novo SNVs in brain-expressed genes, using the empirical data for per-base mutation rates and taking into account the actual distribution of gene sizes and GC content across the genome (Supplementary Information). We calculated probabilities (P) and the false discovery rate (Q) based on a wide range of assumptions regarding the number of genes conferring ASD risk (Supplementary Fig. 7; Fig. 2 ). On the basis of 150,000 iterations, we determined that under all models, two or more nonsense and/or splice site de novo mutations were highly unlikely to occur by chance (P 5 0.008; Q 5 0.005; Supplementary Information; Fig. 2a) . Importantly, these thresholds were robust both to sample size, and to variation in our estimates of locus heterogeneity. Similarly, in our sample, two or more nonsense or splice site de novo mutations remained statistically significant when the simulation was performed using the lower bound of the 95% confidence interval for the estimate of de novo mutation rates in probands ( Supplementary Fig. 7 ). Only a single gene in our cohort, SCN2A, met these thresholds (P 5 0.008; Fig. 2a) , with two probands each carrying a nonsense de novo SNV (Table 2 ). This finding is consistent with a wealth of data showing overlap of genetic risks for ASD and seizure 8 . Gain of function mutations in SCN2A are associated with a range of epilepsy phenotypes; a nonsense de novo mutation has been described in a patient with infantile epileptic encephalopathy and intellectual decline 9 , de novo missense mutations with variable electrophysiological effects have been found in cases of intractable epilepsy 10 , and transmitted rare missense mutations have been described in families with idiopathic ASD 11 . Of note, the individuals in the SSC carrying the nonsense de novo SNVs have no history of seizure.
We then considered whether alternative approaches described in the recent literature 4, 12 , including identifying multiple de novo events in a single individual or predicting the functional consequences of missense mutations, might help identify additional ASD-risk genes. However, we found no differences in the distribution or frequency of multiple de novo events within individuals in the case versus the control groups (Fig. 1c) . In addition, when we examined patients carrying large de novo ASD-risk CNVs, we found a trend towards fewer non-synonymous de novo SNVs (Supplementary Fig. 11 ; Supplementary Information). Consequently, neither finding supported a 'two de novo hit' hypothesis. Similarly, we found no evidence that widely used measures of conservation or predictors of protein disruption, such as PolyPhen2 13 , SIFT 14 , GERP 15 , PhyloP 16 or Grantham Score
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, either alone or in combination differentiated de novo non-synonymous SNVs in probands compared to siblings (Supplementary Fig. 9 ; Supplementary Information). Additionally, among probands, the de reliably distinguishes risk-associated mutations. a, Results of a simulation experiment modelling the likelihood of observing two independent nonsense/ splice site de novo mutations in the same brain-expressed gene among unrelated probands. We modelled the observed rate of de novo brain-expressed mutations in probands and siblings, gene size, GC content and varying degrees of locus heterogeneity, including 100, 333, 667 or 1,000 ASD-contributing genes, as well as using the top 1% of genes derived from a model of exponential distribution of risk (indicated by colour). A total of 150,000 iterations were run. The rate of occurrences of two or more de novo variants in non-ASD genes was used to estimate the P-value ( Supplementary Fig. 7 ) while the ratio of occurrences of two or more de novo variants in non-ASD genes to similar occurrences in ASD genes was used to estimate the false discovery rate (Q). The identification of two independent nonsense/splice site de novo variants in a brain-expressed gene in this sample provides significant evidence for ASD association (P 5 0.008; Q 5 0.005) for all models. This observation remained statistically significant when the simulation was repeated using the lower bound of the 95% confidence interval for the estimate of the de novo mutation rate in probands ( Supplementary Fig. 7) . b, The simulation described in a was used to predict the number of genes that will be found to carry two or more nonsense/ splice site de novo mutations for a sample of a given size (specified on the x axis). c, The simulation was repeated for non-synonymous de novo mutations. The identification of three or more independent non-synonymous de novo mutations in a brain-expressed gene provides significant evidence for ASD association (P , 0.05; Q , 0.05) in the sample reported here, however these thresholds are sensitive both to sample size and heterogeneity models.
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novo SNVs in our study were not significantly over-represented in previously established lists of synaptic genes [18] [19] [20] , genes on chromosome X, autism-implicated genes 2 , intellectual disability genes 2 , genes within ASD-risk associated CNVs 3 or de novo non-synonymous SNVs identified in schizophrenia probands 12, 21 . Finally we conducted pathway and protein-protein interaction analyses 22 for all non-synonymous de novo SNVs, all brain-expressed non-synonymous de novo SNVs and all nonsense and splice site de novo SNVs (Supplementary Fig. 9, 10 ; Supplementary Information) and did not find a significant enrichment among cases versus controls that survived correction for multiple comparisons, though these studies were of limited power.
These analyses demonstrate that neither the type nor the number of de novo mutations observed solely in a single individual provides significant evidence for association with ASD. Moreover, we determined that in the SSC cohort at least three, and most often four or more, brain-expressed non-synonymous de novo SNVs in the same gene would be necessary to show a significant association ( Fig. 2c;  Supplementary Figs 7, 8) . Unlike the case of disruptive nonsense and splice site mutations, these simulations were highly sensitive to both sample size and heterogeneity models ( Fig. 2c ; Supplementary  Figs 7, 8 ; Supplementary Information).
Finally, at the completion of our study, we had the opportunity to combine all de novo events in our sample with those identified in an independent whole-exome analysis of non-overlapping Simons Simplex families that focused predominantly on trios 23 . From a total of 414 probands, two additional genes were found to carry two highly disruptive mutations each, KATNAL2 (katanin p60 subunit A-like 2) (our results and ref. Overall, our results substantially clarify the genomic architecture of ASD, demonstrate significant association of three genes-SCN2A, KATNAL2 and CHD8-and predict that approximately 25-50 additional ASD-risk genes will be identified as sequencing of the 2,648 SSC families is completed (Fig. 2b) . Rare non-synonymous de novo SNVs are associated with risk, with odds ratios for nonsense and splice-site mutations in the range previously described for large multigenic de novo CNVs 3 . It is important to note that these estimates reflect a mix of risk and neutral mutations in probands. We anticipate that the true effect size for specific SNVs and mutation classes will be further clarified as more data accumulate. From the distribution of large multi-genic de novo CNVs in probands versus siblings, we previously estimated the number of ASD-risk loci at 234 (ref. 3) . Using the same approach, the current data result in a point estimate of 1,034 genes, however the confidence intervals are large and the distribution of this risk among these loci is unknown (Supplementary Information). What is clear is that our results strongly support a high degree of locus heterogeneity in the SSC cohort, involving hundreds of genes or more. Finally, via examination of mutation rates in well-matched controls, we have determined that the observation of highly disruptive de novo SNVs clustering within genes can robustly identify risk-conferring alleles.
The focus on recurrent rare de novo mutation described here provided sufficient statistical power to identify associated genes in a relatively small cohort-despite both a high degree of locus heterogeneity and the contribution of intermediate genetic risks. This approach promises to be valuable for future high-throughput sequencing efforts in ASD and other common neuropsychiatric disorders.
METHODS SUMMARY
Sample selection. In total 238 families (928 individuals) were selected from the SSC 5 . Thirteen families (6%) did not pass quality control, leaving 225 families (200 quartets, 25 trios) for analysis (Supplementary Data 1) . Of the 200 quartets, 194 (97%) probands had a diagnosis of autism and 6 (3%) were diagnosed with ASD; the median non-verbal IQ was 84. Exome capture, sequencing and variant prediction. Whole-blood DNA was enriched for exonic sequences through hybridization with a NimbleGen custom array (N 5 210) or EZExomeV2.0 (N 5 718). Captured DNA was sequenced using an Illumina GAIIx (N 5 592) or HiSeq 2000 (N 5 336). Short read sequences were aligned to hg18 with BWA 6 , duplicate reads were removed and variants were predicted using SAMtools 7 . Data were normalized within families by only analysing bases with at least 20 unique reads in all family members. De novo predictions were made blinded to affected status using experimentally verified thresholds (Supplementary Information). All de novo variants were confirmed using Sanger sequencing blinded to affected status. Gene annotation. Variants were analysed against RefSeq hg18 gene definitions; in genes with multiple isoforms the most severe outcome was chosen. All nonsense and canonical splice site variants were present in all RefSeq isoforms. A variant was listed as altering the splice site only if it disrupted canonical 2-base-pair acceptor (AG) or donor (GT) sites. Brain-expressed genes were identified from expression array analysis across 57 post-mortem brains (age 6 weeks post conception to 82 years) and multiple brain regions; 80% of RefSeq genes were included in this subset 24 .
Full Methods and any associated references are available in the online version of the paper at www.nature.com/nature.
